Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
Architects: Cardiovascular, Cardiac & Cardiology Companies _ Heart Valves, Ventricular Assist (LVAD,pVAD), Artificial Heart

Sadra Medical

Attachments

*Portfolio Companies: Accuitive Medical Ventures
*Portfolio Companies: Finistere Partners
Architects: Cardiovascular, Cardiac & Cardiology Companies _ Heart Valves, Ventricular Assist (LVAD,pVAD), Artificial Heart
Companies: Acquired_(M&A)
Finance & Acquisitions: Boston Scientific

2010: Boston Scientific Acquires Sadra for $193M Upfront, Gets Device To Fix Heart Valves
As many as 3 million people in U.S. have aortic valve stenosis
By developing a highly effective aortic valve replacement that is designed to reduce the risks and morbidity associated with open surgical valve replacement, Sadra Medical seeks to provide a therapeutic option for patients who are not being treated today.
Developing innovative new therapies for the treatment of aortic valve disease.
Founded 2009
However, only a Small Percentage of Those Are Treated with the Current Standard of Care, Valve Replacement during Open-heart Surgery Using Cardiopulmonary Bypass.
Los Gatos, California
Minimally invasive alternatives to traditional surgical valve replacement, Sadra Medical
Sadra Medical Raises $19 Million In Series B Financing (2006)
Sadra Medical Raises $30 Million Series C (2009)
Sadra Medical Raises $9 Million In Series A Financing (2004)
Sadra’s breakthrough is a technology it calls the Lotus™ Valve System, the first fully repositionable prosthesis for percutaneous aortic valve replacement.
The round was led by Accuitive Medical Ventures, and includes existing investors Boston Scientific, Finistere, Firstmark Capital, Oakwood, ONSET Ventures, and SV Life Sciences.
Treatment of aortic valve disease remains a significant and growing unmet clinical need.